Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Shunda Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3506-7948; OpenAlex author ID A5045009769. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 6 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. Prevalence, clinicopathological features, and prognosis of diabetes in pancreatic cancer: A single-center retrospective cohort study of 1620 patients. Co-author DOI 10.1016/j.pan.2025.11.004↗
  2. Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferroptosis via regulating SCD1-mediated unsatur… Co-author DOI 10.1186/s13062-023-00421-6↗
  3. ROBO2 hampers malignant biological behavior and predicts a better prognosis in pancreatic adenocarcinoma. Co-author DOI 10.1080/00365521.2021.1930144↗
  4. CD44+ Circulating Tumor Endothelial Cells Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After Radical Surgery: A Pilot Study. Co-author DOI 10.2147/cmar.s309115↗
  5. Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy. Co-author DOI 10.1111/jcmm.15684↗
  6. Research Progress on Slit/Robo Pathway in Pancreatic Cancer: Emerging and Promising. Co-author DOI 10.1155/2020/2845906↗
  7. High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro. Co-author DOI 10.12659/msm.926432↗
  8. Pancreatic cancer with ovarian metastases: A case report and review of the literature. Co-author DOI 10.12998/wjcc.v8.i21.5380↗
  9. Glutathione S-Transferase Mu-3 Predicts a Better Prognosis and Inhibits Malignant Behavior and Glycolysis in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01539↗
  10. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Co-author PMID 32774994↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Menghua Dai · 7 shared papers, 2020–2021 · strength 0.97
  2. Cheng Ding · 5 shared papers, 2020–2021 · strength 0.66
  3. Yupei Zhao · 4 shared papers, 2020 · strength 0.55
  4. Lei You · 4 shared papers, 2020 · strength 0.55
  5. Shuisheng Zhang · 2 shared papers, 2023–2025 · strength 0.43
  6. Chengfeng Wang · 2 shared papers, 2023–2025 · strength 0.43
  7. Hanyu Zhang · 2 shared papers, 2020–2021 · strength 0.27
  8. Xu Che · 1 shared paper, 2025 · strength 0.26
  9. Shuai Xiang · 1 shared paper, 2025 · strength 0.26
  10. Yunlong Li · 1 shared paper, 2025 · strength 0.26
  11. Yongxing Du · 1 shared paper, 2025 · strength 0.26
  12. Qifeng Xiao · 1 shared paper, 2023 · strength 0.17
  13. Hu Ren · 1 shared paper, 2023 · strength 0.17
  14. Jianwei Zhang · 1 shared paper, 2023 · strength 0.17
  15. Dan Li · 1 shared paper, 2023 · strength 0.17
  16. Cheng Xing · 1 shared paper, 2021 · strength 0.15
  17. Pengyu Li · 1 shared paper, 2021 · strength 0.15
  18. Huanwen Wu · 1 shared paper, 2020 · strength 0.15
  19. Liang Zhu · 1 shared paper, 2020 · strength 0.15
  20. Yu-Pei Zhao · 1 shared paper, 2020 · strength 0.15
  21. Yizhi Wang · 1 shared paper, 2021 · strength 0.14
  22. Jinshou Yang · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.